logo
Covid-19 Likely Originated From Wildlife Trade, Not Lab Leak, Researchers Claim

Covid-19 Likely Originated From Wildlife Trade, Not Lab Leak, Researchers Claim

NDTV08-05-2025
A new genetic study bolsters the theory that COVID-19 originated from the wildlife trade, challenging claims of a lab leak. Researchers traced the virus's origins to animals sold in Wuhan markets, adding fuel to the ongoing debate amid US-China tensions.
The findings, published in Cell on May 7, 2025, point to a natural spillover, highlighting the persistent risks of zoonotic diseases stemming from the wildlife trade.
Researchers at the University of California San Diego School of Medicine and their colleagues concluded that the ancestor of SARS-CoV-2, the virus that causes COVID-19, emerged just years before the pandemic began. The virus left its origin in Western China or Northern Laos just years before the emergence, travelling nearly 2,700 kilometres to Central China. This timeframe is too short for natural dispersal by its primary host, the horseshoe bat, suggesting it "hitched a ride" via the wildlife trade, similar to the SARS outbreak in 2002.
"When two different viruses infect the same bat, sometimes what comes out of that bat is an amalgam of different pieces of both viruses," said co-senior author Joel Wertheim, PhD, a professor of medicine at UC San Diego School of Medicine's Division of Infectious Diseases and Global Public Health. "Recombination complicates our understanding of the evolution of these viruses because it results in different parts of the genome having different evolutionary histories."
To overcome this, the researchers focused on non-recombining regions of the viral genomes, allowing them to more accurately reconstruct the evolutionary history.
The study indicates that sarbecoviruses related to SARS-CoV-1 and SARS-CoV-2 have circulated around Western China and Southeast Asia for millennia, spreading at similar rates as their horseshoe bat hosts.
"Horseshoe bats have an estimated foraging area of around 2-3 km and a dispersal capacity similar to the diffusion velocity we estimated for the sarbecoviruses related to SARS-CoV-2," said co-senior author Simon Dellicour, Ph.D., head of the Spatial Epidemiology Lab at Université Libre de Bruxelles and visiting professor at KU Leuven.
The analysis further revealed that the most recent sarbecovirus ancestors of both SARS-CoV-1 and SARS-CoV-2 left their points of origin less than 10 years before infecting humans more than a thousand kilometres away.
"We show that the original SARS-CoV-1 was circulating in Western China - just one to two years before the emergence of SARS in Guangdong Province, South Central China, and SARS-CoV-2 in Western China or Northern Laos - just five to seven years before the emergence of COVID-19 in Wuhan," said Jonathan E. Pekar, PhD, a 2023 graduate of the Bioinformatics and Systems Biology programme at UC San Diego School of Medicine, now a postdoctoral researcher at the University of Edinburgh.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO

Economic Times

time3 minutes ago

  • Economic Times

Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO

Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'

Eris Lifesciences betting on insulin expertise to boost its GLP-1 play
Eris Lifesciences betting on insulin expertise to boost its GLP-1 play

Mint

time6 minutes ago

  • Mint

Eris Lifesciences betting on insulin expertise to boost its GLP-1 play

Eris Lifesciences is gearing up to take advantage of India's booming diabetes-obesity market. The Ahmedabad-based drugmaker stands to gain in the country's human insulin market as innovator Novo Nordisk vacates, and it is betting on its insulin platform to grab a significant share in the anti-obesity market. 'We have a very successful insulin business with close to 10% market share in the country now. And any company that sells insulin well has been able to do GLP-1 very well," CEO Krishnakumar Vaidyanathan toldMintin an interview. Danish drugmaker Novo Nordisk, which is the innovator of blockbuster anti-obesity drugs Ozempic and Wegovy, is also a market leader in insulin, with an over 50% market share in India. The market for weight loss drugs in India was over ₹600 crore in July 2025. Also Read: Piramal Pharma's loss narrows to Rs82 crore in June quarter Vaidyanathan explained that the insulin business involves building a patient service and care platform, which goes beyond just selling the product. '...there is active support from Eris' side at the patient's residence…given this insulin platform, we are very confident that we'll be able to make a success of GLP-1 as well, because it will ride on this platform," he said. Eris says they have a 'one of a kind" patient service model where they train patients to use insulin, while Novo has a service model as well and a wide network of physicians. GLP-1s or glucagon-like peptide-1 agonists are a class of drugs used to treat type-2 diabetes and obesity, which mimic the GLP-1 hormone produced in the gut to regulate blood sugar and appetite. Eris plans to rely on third parties for Active Pharmaceutical Ingredients (APIs), but will eventually bring regular semaglutide in-house. It will depend on third parties for the synthetic semaglutide API. Eris launched liraglutide, a GLP-1, in India last year and plans to be among the first wave of launches for generic semaglutide, which goes off patent in March 2026. It is not the only one. India's top drugmakers, including Dr Reddy's,Cipla, Sun Pharma,Zydus Lifesciences, and Natco, are gearing up to launch the generic semaglutide next year. The firm also has a pipeline of standalone insulin analogues and insulin analogues with GLP-1 combinations in preclinical and clinical trials. Insulin dominance Earlier this year, Novo Nordisk announced the rollback of pen-filled versions of its best-selling Human Mixtard insulin. While the vial versions will still be sold, this opens up a huge market for domestic players to fill in the country's ₹4,500 crore insulin market. Eris acquired the Insugen and Basalog brands fromBiocon Biologics last year as part of a larger deal to acquire its branded formulations business. It also sells Xsulin through a joint venture with MJ Biopharma. Also Read: Jashvik Capital acquires stake in pharma software firm for ₹400 crore Apart from innovators Novo Nordisk andSanofi, which dominate the Indian insulin market, Lupin, which acquired Eli Lilly's Huminsulin brand last year, is a key domestic player. 'So this whole democratisation of insulins and GLP-1s is something that is going to happen. The ball has been set rolling," said Vaidyanathan. Eris expects to see increased sales from recombinant human insulin (RHI) pen products in November and December as innovator inventory runs out. The company is also planning to in-source its insulin and GLP-1 production at a later stage. The company commenced production of insulin vials at its Bhopal facility in Q1FY26, and expects to start cartridge production by Q4FY26. 'Our strategy has always been that, once we deem that a product is big and strategically important, then we bring it in-house," said Vaidyanathan. Eris Lifesciences reported its Q1FY26 results on Tuesday, with its consolidated revenue up 7.4% year-on-year to ₹773 crore. Its Ebitda for the quarter stood at ₹277 crore, up 11% YoY with a 36% Ebitda margin. Net profit was up 41% to ₹125 crore. The drugmaker is focused on increasing profitability and paring down debt in FY26. Also Read: Sun Pharma net profit falls on US antitrust settlement, drug impairment costs 'All of this will be accompanied by a significant acceleration in the EPS (earnings per share) and the return ratios," said Vaidyanathan. Its EPS in Q1 was ₹9.2, and the company expects a 50% EPS growth in FY26. The company's net debt in Q1FY26 was ₹2,317 crore, and it aims to reduce debt to ₹1,800 crore by the end of the year.

Build readiness against rising dirty-war risks
Build readiness against rising dirty-war risks

Hindustan Times

time36 minutes ago

  • Hindustan Times

Build readiness against rising dirty-war risks

This August 6 marks 80 years of the US's nuclear bombing of Hiroshima, Japan, which permanently altered the trajectory of global security and warfare. The two bombs dropped in 1945, on Hiroshima and on Nagasaki three days later, killed over 350,000 people instantly and left another 400,000 dead within a few months — introducing the world to the devastating potential of weapons of mass destruction (WMDs). At the time, the yield or intensity of these weapons was relatively modest compared to the nuclear arsenal that exists today. Today, the world faces far more advanced, lethal, and widespread threats under the growing umbrella of 'dirty wars'. The scale of suffering and devastation is beyond comprehension, and today's weapons are exponentially more powerful. There are estimated to be over 12,000 nuclear warheads in the world. Many of the modern strategic nuclear weapons are thermonuclear weapons, having yields equivalent to a 100 kilo tonnes (KT) of TNT and above. This has the potential to destroy the world as we know it many times over. Tactical nuclear weapons can be 50 KT and less. Each WMD category brings its own horrors: While nuclear weapons incinerate cities, biological and chemical agents work invisibly, silently, and over time. (AFP) The India-Pakistan conflict captures the world's attention given both have nuclear capabilities. A nuclear bomb's destruction extends far beyond its immediate blast radius. It generates an intense fireball, a blinding flash, a shockwave and, most dangerously, ionising radiation. The radioactive mushroom cloud not only contaminates the target, but reaches far-flung regions, depending on wind conditions — rendering vast areas uninhabitable for decades. In the Cold War era, WMDs were broadly categorised under the NBC triad — nuclear, biological, and chemical weapons. Over time, radiological was added to this, creating the term CBRN. Each category brings its own horrors: While nuclear weapons incinerate cities, biological and chemical agents work invisibly, silently, and over time. Chemical weapons, although banned under international law, are still accessible to States and non-State actors. They can be created using widely available industrial and pharmaceutical chemicals, turning everyday compounds into agents of mass death. Sarin, VX, chlorine, and mustard gas are examples. Equally alarming are biological weapons — viruses and bacteria designed to infect and kill populations indiscriminately. The Covid-19 pandemic gave the world a preview to the havoc a simple virus can unleash, even if accidental. But when weaponised and intentionally released, pathogens could cripple societies, economies, and militaries in a matter of days. The proliferation of biological research facilities worldwide, some poorly regulated, raises grave concerns. The Wuhan lab controversy underlined the thin line between scientific exploration and potential dual use for bio-warfare. Biological and radiological warfare has become the preferred 'silent weapon' of the future, and many nations are covertly advancing such capabilities under the guise of health research. A critical issue lies in the imbalance of offensive and defensive capacities. While many nations possess the capability to launch CBRN attacks, few are adequately prepared or capable of defending themselves. Countries like China have built subterranean tunnel networks housing military assets in case of nuclear or chemical strikes. Such preparation indicates an evolving mindset — wars will no longer be limited to borders or frontlines. They will target critical infrastructure, command-and-control (C2) nodes, urban populations, and national willpower itself. Missiles, aircraft, and now drones can deliver munitions deep into the hinterland. In a dirty war, collateral damage will be immense — not just military installations but power grids, hospitals, transport systems, and even the financial sector can be targeted through kinetic, cyber, or biological means. Even conventional missile warheads will be toxic enough to cause permanent damage to the lungs, heart and brain. A dirty war is now a creeping reality. Technology has empowered even smaller nations and insurgent groups to wield devastating power. Leaders today appear less tolerant, more reactive, and increasingly reliant on first-strike doctrines. What can nations do? Preparedness must be comprehensive. This includes building CBRN shelters in key cities and military bases and training first responders and civilians for CBRN scenarios. It should be essential to stockpile antidotes, protective suits, and detection systems. The civil defence and NDMA should conduct regular drills and heighten awareness. Securing borders and labs against bio-accidents/terrorism, investing in early warning, air defence and missile defence systems, especially empowered by space and cyber domains would be essential. Civil defence needs revival. Strategic deterrence must go hand-in-hand with societal resilience. Dirty wars may not be declared, but their impact will be undeniable. Let us prepare, not panic. PJS Pannu is a retired lieutenant general with the Indian Army. The views expressed are personal.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store